Tonga vs Tuvalu: The number of people with susceptibility test result for rifampicin
Tonga
100
in 2021
Tuvalu
100
in 2021
Tonga rank
2nd
Tuvalu rank
2nd
The number of people with susceptibility test result for rifampicin over time
- Tonga
- Tuvalu
How they compare
Tonga currently reports 100 against 100 in Tuvalu, a difference of 0.
The two have swapped places 4 times across 5 shared years of data; in 2017 it was Tuvalu ahead.
Tonga ranks 2nd and Tuvalu ranks 2nd of 146 countries.
Across the 2 decades both report, Tonga averaged higher in 1 and Tuvalu in 1.
Head to head by decade
| Decade | Tonga | Tuvalu | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 100 | 114.29 | 14.29 | Tuvalu |
| 2020s | 100 | 96.88 | 3.12 | Tonga |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Tonga or Tuvalu?
- Tonga, at 100 against 100 in Tuvalu as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Tonga and Tuvalu?
- 0, with Tonga ahead.
- How many years of comparable data are there for Tonga and Tuvalu?
- 5 years are reported by both, from 2017 to 2021.
- How do Tonga and Tuvalu rank globally for the number of people with susceptibility test result for rifampicin?
- Tonga ranks 2nd and Tuvalu ranks 2nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.